Prescribing cannabis for harm reduction
Copyright policy )Prescribing cannabis for harm reduction
Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and mortality rates associated with prescription pain medications.
cannabis, neuropathic pain, Public Health, Environmental and Occupational Health, opioids, Medicine (miscellaneous), ethics, cannabinoids, Psychiatry and Mental health, Commentary, harm reduction, Public aspects of medicine, RA1-1270, chronic pain
cannabis, neuropathic pain, Public Health, Environmental and Occupational Health, opioids, Medicine (miscellaneous), ethics, cannabinoids, Psychiatry and Mental health, Commentary, harm reduction, Public aspects of medicine, RA1-1270, chronic pain
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).78 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!